Abstract：
BACKGROUND: Studies have found that c-Met plays a critical role in the progression of solid tumors. This study aimed to investigate the expression of c-Met in gastric cancer (GC) and its correlation with preoperative serum tumor markers and prognosis, in order to provide a more theoretical basis for targeting c-Met in the treatment of GC.
METHODS: Ninety-seven patients who underwent curative gastrectomy in our hospital from December 2013 to September 2015 were included in this study. The tissue microarray was constructed by paraffin-embedded tumor tissue of enrolled patients, including 97 GC points and 83 paracancerous points. Then, it was used for c-Met immunohistochemical staining, followed by an immunological H-score. The clinical baseline data and 5-year survival of patients with low and high c-Met expression were compared. Besides, the correlation between the expression of c-Met in tumor tissues and preoperative serum tumor markers was investigated. Finally, multivariate Cox regression analysis was used to explore the survival risk factors of patients.
RESULTS: c-Met has a high expression rate in GC tissues 64.95% (63/97). The expression of c-Met was significantly different in different clinicopathological stages (p < 0.05); the high expression group also had a higher M stage and clinicopathological stage of GC. The correlation test between the c-Met H-score and CA125 was statistically significant (p = 0.004), indicating a positive correlation. Furthermore, high c-Met expression correlated with poor overall survival (OS) for 5 years (p = 0.005). It was also found that the high expression of c-Met in stage I-II patients was correlative with poor OS for 5 years (p = 0.026), while stage III-IV patients had no statistical significance (p > 0.05). Multivariate Cox regression analysis showed that c-Met might be an independent risk factor for survival 5 years after surgery.
CONCLUSIONS: This study found that the high expression of c-Met in GC tissues was associated with poor 5-year OS in GC patients and was an independent risk factor for 5-year survival after curative gastrectomy. The expression of c-Met in GC tissues was also positively correlated with preoperative serum CA125.
METHODS: Ninety-seven patients who underwent curative gastrectomy in our hospital from December 2013 to September 2015 were included in this study. The tissue microarray was constructed by paraffin-embedded tumor tissue of enrolled patients, including 97 GC points and 83 paracancerous points. Then, it was used for c-Met immunohistochemical staining, followed by an immunological H-score. The clinical baseline data and 5-year survival of patients with low and high c-Met expression were compared. Besides, the correlation between the expression of c-Met in tumor tissues and preoperative serum tumor markers was investigated. Finally, multivariate Cox regression analysis was used to explore the survival risk factors of patients.
RESULTS: c-Met has a high expression rate in GC tissues 64.95% (63/97). The expression of c-Met was significantly different in different clinicopathological stages (p < 0.05); the high expression group also had a higher M stage and clinicopathological stage of GC. The correlation test between the c-Met H-score and CA125 was statistically significant (p = 0.004), indicating a positive correlation. Furthermore, high c-Met expression correlated with poor overall survival (OS) for 5 years (p = 0.005). It was also found that the high expression of c-Met in stage I-II patients was correlative with poor OS for 5 years (p = 0.026), while stage III-IV patients had no statistical significance (p > 0.05). Multivariate Cox regression analysis showed that c-Met might be an independent risk factor for survival 5 years after surgery.
CONCLUSIONS: This study found that the high expression of c-Met in GC tissues was associated with poor 5-year OS in GC patients and was an independent risk factor for 5-year survival after curative gastrectomy. The expression of c-Met in GC tissues was also positively correlated with preoperative serum CA125.
摘要：
背景：研究发现c-Met在实体瘤的进展中起着关键作用。本研究旨在探讨c-Met在胃癌组织中的表达及其与术前血清肿瘤标志物和预后的关系。为靶向c-Met治疗GC提供更多的理论依据。
方法：选择2013年12月至2015年9月在我院行根治性胃切除术的患者97例。组织微阵列由入选患者的石蜡包埋肿瘤组织构建，包括97个GC点和83个异常点。然后，用于c-Met免疫组织化学染色,然后是免疫学H评分。比较低和高c-Met表达患者的临床基线数据和5年生存率。此外,探讨c-Met在肿瘤组织中的表达与术前血清肿瘤标志物的相关性。最后,采用多因素Cox回归分析探讨患者生存危险因素。
结果：c-Met在GC组织中的高表达率为64.95%(63/97)。c-Met的表达在分歧临床病理分期有明显差别(p<0.05)；高表达组也有较高的GCM分期和临床病理分期。c-MetH评分与CA125的相关性检验有统计学意义(p=0.004),表明正相关。此外，c-Met高表达与5年总生存期(OS)差相关(p=0.005).还发现，在I-II期患者中c-Met的高表达与5年的不良OS相关（p=0.026）。而III-IV期患者无统计学意义(p>0.05)。多因素Cox回归分析显示c-Met可能是影响术后5年生存率的独立危险因素。
结论：本研究发现，GC组织中c-Met的高表达与GC患者5年OS差相关，是根治性胃切除术后5年生存的独立危险因素。GC组织中c-Met的表达与术前血清CA125呈正相关。
方法：选择2013年12月至2015年9月在我院行根治性胃切除术的患者97例。组织微阵列由入选患者的石蜡包埋肿瘤组织构建，包括97个GC点和83个异常点。然后，用于c-Met免疫组织化学染色,然后是免疫学H评分。比较低和高c-Met表达患者的临床基线数据和5年生存率。此外,探讨c-Met在肿瘤组织中的表达与术前血清肿瘤标志物的相关性。最后,采用多因素Cox回归分析探讨患者生存危险因素。
结果：c-Met在GC组织中的高表达率为64.95%(63/97)。c-Met的表达在分歧临床病理分期有明显差别(p<0.05)；高表达组也有较高的GCM分期和临床病理分期。c-MetH评分与CA125的相关性检验有统计学意义(p=0.004),表明正相关。此外，c-Met高表达与5年总生存期(OS)差相关(p=0.005).还发现，在I-II期患者中c-Met的高表达与5年的不良OS相关（p=0.026）。而III-IV期患者无统计学意义(p>0.05)。多因素Cox回归分析显示c-Met可能是影响术后5年生存率的独立危险因素。
结论：本研究发现，GC组织中c-Met的高表达与GC患者5年OS差相关，是根治性胃切除术后5年生存的独立危险因素。GC组织中c-Met的表达与术前血清CA125呈正相关。
